Status:
COMPLETED
Multiple Myeloma Prognostic Indices
Lead Sponsor:
Assiut University
Conditions:
Multiple Myeloma
Hematologic Diseases
Eligibility:
All Genders
Brief Summary
The aim of this study was to evaluate the impact of albumin / fibrinogen ratio, blood viscosity and RDW on the prognosis of a newly diagnosed MM patients
Detailed Description
Multiple myeloma (MM) is a hematologic neoplasm of plasma cells that arises in the bone marrow, manifest by bone pain, pathologic fractures, anemia, renal insufficiency and recurrent infections. Treat...
Eligibility Criteria
Inclusion
- Patients newly diagnosed with MM according to International Myeloma Working Group criteria 2016.
Exclusion
- Patient previously diagnosed MM and started treatment or in post treatment follow up
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2025
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06095752
Start Date
April 1 2023
End Date
April 30 2025
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University hospital
Asyut, Asyut Governorate, Egypt, 88